Photo from wikipedia
Patients with refractory status epilepticus (RSE) have failed treatment with benzodiazepines and ≥1 second‐line intravenous (IV) antiseizure medication (ASM). Guidelines recommend IV anesthesia when second‐line ASMs have failed, but potential… Click to show full abstract
Patients with refractory status epilepticus (RSE) have failed treatment with benzodiazepines and ≥1 second‐line intravenous (IV) antiseizure medication (ASM). Guidelines recommend IV anesthesia when second‐line ASMs have failed, but potential harms can outweigh the benefits. Novel treatments are needed to stop and durably control RSE without escalation to IV anesthetics. Ganaxolone is an investigational neuroactive steroid in development for RSE treatment. This study's objective was to determine the appropriate dosing for IV ganaxolone in RSE and obtain a preliminary assessment of efficacy and safety.
Journal Title: Epilepsia
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!